Novartis | NOVN - Ebit


Novartis reported $4.06B in EBIT for its fiscal quarter ending in December of 2025.





Ebit Change Date
AbbVie USD 5.81B 4.36B Dec/2025
Alcon AG USD 317M 17M Dec/2025
Almirall EUR 30.23M 12.8M Dec/2025
Amgen USD 3.96B 464M Dec/2025
AstraZeneca USD 2.97B 4.48B Dec/2025
Autolus Therapeutics Ltd USD -72.47M 845K Dec/2025
Bayer EUR 1.11B 1.51B Dec/2025
Biogen USD 659.6M 157M Sep/2025
Bristol-Myers Squibb USD 3.47B 567M Dec/2025
Eli Lilly USD 8.99B 1.57B Dec/2025
Fresenius EUR 713M 139M Dec/2025
Fresenius Medical Care EUR 663M 213.06M Dec/2025
Galapagos EUR 780.56M 822.23M Dec/2025
Genmab DKK 260M 199M Dec/2025
Gilead Sciences USD 2.96B 551M Dec/2025
GlaxoSmithKline GBP 1.44B 1.35B Dec/2025
GRIFOLS EUR 352.11M 20.18M Sep/2025
Hikma Pharmaceutical USD 348M 31M Dec/2025
J&J USD 5.11B 2.3B Dec/2025
Lonza CHF 673M 54M Jun/2025
Merck EUR 474M 738M Dec/2025
Merck USD 6.24B 1.32B Dec/2025
Novartis USD 4.06B 530M Dec/2025
Novartis USD 4.06B 413M Dec/2025
Novo Nordisk DKK 32.38B 1.7B Dec/2025
Orion EUR 328.1M 207.1M Dec/2025
Pfizer USD 4.65B 71M Dec/2025
Philips EUR 719M 390M Dec/2025
Recordati EUR 278.23M 112.58M Dec/2025
Regeneron Pharmaceuticals USD 898.6M 211.3M Dec/2025
Roche Holding CHF 9.56B 2.1B Dec/2025
Sanofi EUR 1.7B 2.17B Dec/2025
UCB EUR 1.29B 571M Dec/2025